Trials / Completed
CompletedNCT06801418
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
A Phase 1, Open-label, Randomized, 2-sequence, 4-period, Fully-replicate, Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Mirati Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a study to evaluate bioequivalence between adagrasib reference tablets and high drug load tablets in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adagrasib | Specified dose on specified days |
Timeline
- Start date
- 2025-02-04
- Primary completion
- 2025-06-19
- Completion
- 2025-06-19
- First posted
- 2025-01-30
- Last updated
- 2025-07-16
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06801418. Inclusion in this directory is not an endorsement.